Company ProfilePremium

Pi Industries Ltd

Company Profile Analysis

Tickers: PIIND.NS, 523642.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Pi Industries Ltd - Company showcase

Year Founded & Workforce

2000

6,300 Employees

Pi Industries Ltd logo

Pi Industries Ltd Employee Contacts

8 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Pi Industries Ltd Overview

PI Industries is India's pre-eminent agrochemical custom synthesis and manufacturing (CSM) franchise and, increasingly, a diversified life-sciences platform. Roughly three-quarters to four-fifths of revenue derives from long-dated, cost-plus-structured contract manufacturing of patented molecules for global crop-protection innovators — a business in which PI is among the top five players worldwide and which carries high switching costs, IP-stewardship credibility built over three decades, and an order book of USD 1.0–1.2 bn. The balance is a domestic branded agri-inputs business, top-ten in India, sold through 15,000+ distributors and ~150,000 retail points. Since FY23 management has deliberately widened the aperture: a pharma CRDMO platform (PI Health Sciences, India–Italy), a global biologicals franchise acquired via Plant Health Care, and an electronic-chemicals venture. FY26 was the trough of a severe global agrochemical destocking cycle — revenue fell 16% and PAT 20% — but the balance sheet is net cash ₹38 bn and debt-free.

MetricFY24FY25FY26
Group headcount (aggregator estimates, wide dispersion)6,3006,7505,000

Third-party trackers disagree materially: Revelio Labs reports 6,762 group employees as at December 2025 (up ~7% YoY); Tracxn reports 4,986 as at 31 May 2026; TheCompanyCheck reports ~3,499 (likely standalone/MCA-filed only). Headcount should be treated as not reliably disclosed in the public sources reviewed. What is verified: PI employs 700+ scientists including 200+ doctorates in R&D (Q1 FY27 presentation), and gender diversity was ~6.2% women in total workforce in FY25, ~9% in management positions (CRISIL, July 2026).


PI Industries operates a two-segment reporting structure (Agro Chemicals; Pharma) that understates the economic reality of four distinct businesses.

Agchem exports / CSM. This is the profit engine, contributing over three-fourths of consolidated revenue (CRISIL, July 2026). PI does not own the molecules it makes here. Global innovators — Japanese, European and US crop-protection majors — bring PI a patented active ingredient, typically early in its life cycle. PI's process-chemistry teams at Udaipur develop a commercially viable synthetic route, scale it through kilo-lab and pilot stages, then manufacture at commercial volume in multipurpose plants (MPPs) in Gujarat. Contracts are long-term and structured on a cost-plus basis with pass-through of key raw-material price movements, which materially insulates gross margin from input-cost volatility (CRISIL, July 2026). The binding constraints on this business are not demand-side marketing but (a) the innovator's own molecule pipeline, (b) PI's ability to win early-stage engagements, and (c) genericisation risk as molecules come off patent. PI's single largest historical product, pyroxasulfone, is the textbook illustration: management was asked directly on the Q4 FY26 call whether, stripping out pyroxasulfone, CSM exports would have grown in FY26 — a question that captures the core investment debate.

Domestic Agri Brands. A five-decade-old branded generics and in-licensing/co-marketing (ILCM) business, top-10 in India. PI in-licenses innovator molecules for the Indian market, formulates and brands them, and distributes through a channel of more than 15,000 distributors and ~150,000 retailers. Flagship brands with multi-year leadership include Nominee Gold (bispyribac-sodium herbicide), Pryvita, and broflanilide-based insecticides. Roughly 20% of consolidated revenue in FY26 (CRISIL).

Biologicals. PI pioneered biological solutions in India and materially expanded the franchise with the August 2024 acquisition of UK AIM-listed Plant Health Care plc, now renamed PI AgSciences. This brings the proprietary PREtec peptide platform and the Harpin αβ protein biostimulant. Gross margins here exceed 60%. Biologicals were ~20% of domestic revenue in FY26 and grew >50% YoY in Q1 FY27.

Pharma (PI Health Sciences). Entered FY24 via three acquisitions. Positioned as an integrated CRDMO — contract research, development and manufacturing of APIs, key starting materials and intermediates — operating an India (Hyderabad) plus Italy (Lodi) model. Still loss-making and in investment phase.

Electronic chemicals. A nascent CSM adjacency leveraging the same process-chemistry and high-purity manufacturing capability. Management targets USD 100 mn revenue in 4–5 years.

Revenue model mix. Predominantly product manufacture-and-sale. There is no subscription revenue. Licensing revenue is currently immaterial but becomes strategically live with Pioxaniliprole, PI's first in-house-discovered new chemical entity, for which management has stated it is in "advanced talks in certain geographies" on out-licensing/distribution partnerships (Q4 FY26 call).

Value-chain position. In CSM, PI sits mid-chain: downstream of commodity intermediates, upstream of the innovator's own formulation and branding. In domestic agri it is fully downstream to the farmer. In biologicals and Pioxaniliprole it is attempting, for the first time, to own the molecule end-to-end — which management explicitly framed on the Q4 FY26 call as "a major shift in the PI way from distributor to global scale manufacturer to reposition as a global innovator."

Customer types. Global agrochemical innovator companies (CSM); Indian distributors, dealers and farmers (domestic); pharmaceutical innovators, biotechs and big pharma (PIHS); electronics/specialty chemical customers.

End-markets. Row crops (rice, wheat, corn, soybean, cotton), horticulture (via the Jivagro brand), pharmaceuticals, and electronics.

Strategy

Stated strategy — management's own framing

Management's articulation on the Q4 FY26 call is the clearest statement of intent: "Today PI stands to move into the next orbit, into the innovator mindset, taking NCEs to the world in Ag, and in Lifesciences building the CRDMO platform and working in Electronic Chemicals." And: "We believe this brings a major shift in the PI way from distributor to global scale manufacturer to reposition as a global innovator with the backbone strength of partnerships across the value chain."

The corporate purpose statement is "Lead with science, technology and human ingenuity to create transformative solutions in life sciences," with the framing "reimagining a healthier planet." Corporate values are codified as four C's: Courageous, Curious, Creative, Caring.

The strategic logic is a three-stage progression PI describes of itself: distributor → global-scale contract manufacturer → global innovator. Stage three is what FY26–FY28 is about, and it is being funded from the cash flows of stage two at precisely the moment stage two is cyclically weak. That tension is the whole story.

Strategic initiatives, last 24 months

InitiativeDateDetail
Plant Health Care acquisition and integrationAug 2024£32.8 mn; global biologicals platform; entities rebranded PI AgSciences through FY25–FY26
PI AgSciences global brand consolidationFY25–FY26PHC entities in UK, US, Spain, Brazil, Mexico renamed under the PI AgSciences banner, unifying the global agriculture business
Pioxaniliprole NCE commercialisationFY26–FY27First indigenously invented Indian insecticide; domestic approval received FY27; global filings underway; out-licensing/distribution partnerships in advanced discussion
US EPA registration, PHC689493 Mar 2026Industry-first foliar-applied biochemical nematicide; third PI AgSciences active ingredient registered in the US
Harpin αβ India approvalFY26Regulatory approval for the flagship biostimulant in the domestic market
Electronic chemicals build-outFY23–ongoing5–7 products launched, ~10 projects in pipeline; target USD 100 mn revenue in 4–5 years
Pharma CRDMO scale-upFY24–ongoingTarget ₹500–600 Cr revenue within 2–3 years; 6 programmes in Phase I/II/III; 4 marquee customers onboarded Q1 FY27; exclusive integrated drug-discovery partnership signed with a biotech
Hyderabad drug-discovery centre of excellenceFY26–FY27Centre of excellence for drug discovery plus CRO facilities to support IND programmes
Lodi (Italy) capability expansionQ1 FY27~₹233 Mn on CDMO capacity, QC laboratory and kilo-lab; AIFA GMP certification renewed
Two new multipurpose plantsQ4 FY26 / Q1–Q2 FY27Commissioning to convert the CWIP build into revenue-generating capacity
SAP S/4HANA implementationFY26Group-wide digital transformation; cited by management as a governance and efficiency milestone
Contingent consideration renegotiationDec 2025One-time settlement with Therachem's erstwhile owners; ₹1,260 Mn write-back; in-house global business development team now replaces external support
PI Foundation incorporationAug 2026Section 8 wholly-owned subsidiary for CSR, initial capital ₹100,000
Revamped domestic go-to-marketFY27Portfolio diversification and expanded product reach
ESG: S&P Global Sustainability Yearbook2024–2026Third consecutive year of inclusion; score improved from 68 (2024) to 77; 98th percentile

Management's medium-term financial targets

TargetMetricTimeframeSource
Revenue growth, FY27Low single digits, positiveFY27Reiterated Q4 FY26 and Q1 FY27 calls
Second-half weightingH2 FY27 stronger than H1 on export recoveryFY27Q1 FY27 call
Capital expenditure₹700–800 CrFY27Q4 FY26 and Q1 FY27 guidance (revised up from ₹500–600 Cr guided at Q3 FY26)
Effective tax rate~24%FY27Q1 FY27 call
Growth-platform investment3–4% of revenue into new businesses and R&DOngoingQ1 FY27 call
Pharma revenue₹500–600 Cr2–3 yearsQ4 FY26
Electronic chemicals revenueUSD 100 mn4–5 yearsQ4 FY26
Biologicals break-even (global)Break-even"Next couple of years"Q4 FY26
Asset turns2.2–2.5x3 yearsManagement commentary
Order bookUSD 1.0–1.2 bn confirmedCurrentCRISIL July 2026; Q1 FY27 presentation

Management withdrew or did not reiterate the double-digit revenue growth aspiration that framed the FY22–FY24 period. CRISIL's upward rating trigger — sustained healthy double-digit revenue growth — is therefore not currently in management's own guidance.

Products & Services

PI does not publish a complete SKU-level catalogue with pricing; pricing models for individual products are not publicly disclosed. The following is assembled from the company website, investor presentations and filings.

Agro Chemicals — CSM export services

OfferingDescriptionTarget customer
Techno-commercial process evaluationAssessment of a client molecule's manufacturability and cost structureGlobal crop-protection innovators
Process developmentRoute scouting, optimisation, impurity profiling at UdaipurInnovators, early lifecycle
Scale-up & technology transferKilo-lab to pilot to commercial transferInnovators
Commercial manufacturing15 fully automated multipurpose plants with DCS across 5 locationsInnovators, long-term supply contracts
Flow chemistryOperationalised at pilot scale FY23; PI Flowtech B.V. as dedicated vehicleInnovators requiring continuous processes
Azide / MMH chemistryHazardous-chemistry capability commercialised FY23Innovators
Electronic chemicalsHigh-purity specialty chemicals; 5–7 products launched, ~10 in pipelineElectronics / semiconductor supply chain

Flagship CSM molecule: Pyroxasulfone — historically PI's single largest export product, manufactured for Kumiai Chemical Industry (Japan). Its patent maturity and consequent genericisation is the single most-discussed structural risk on PI's earnings calls. Molecules commercialised in the trailing three years accounted for 16–18% of export business as at Q1 FY26 and grew 46% YoY. PI commercialised 5 new molecules in exports in FY26 and guides to 5+ in FY27.

Agro Chemicals — Domestic branded portfolio

BrandCategoryNotes
Nominee GoldHerbicide (bispyribac-sodium)Long-standing market leader; flagship rice herbicide
PryvitaInsecticideNamed by management as a multi-year leadership brand
Broflanilide-based productsInsecticideIn-licensed innovator chemistry; leadership brand
AwkiraHerbicide (wheat)Launched Oct 2019
DistruptorInsecticideLaunched FY23
BrofreyaInsecticideLaunched FY23
DinoaceInsecticideLaunched FY23
TaurusInsecticideLaunched FY23
ProvideHerbicideLaunched FY23
SectinFungicideLaunched FY23
TomatoughBiostimulantLaunched FY23
AlcorHerbicideLaunched FY24–FY26 window
FixitHerbicideLaunched FY24–FY26 window
PressedoInsecticideLaunched FY24–FY26 window
DoritoInsecticideLaunched FY24–FY26 window
Biovita (granules and liquid)Specialty / biostimulantAscophyllum nodosum seaweed-based
Super SpreaderAdjuvantSpecialty product
HumesolSpecialtyHumic/fulvic acid-based
VEGFRULegacy formulation brandOriginal agchem marketing brand
Jivagro (separate subsidiary/brand)Horticulture portfolioDedicated horticulture go-to-market

Four new domestic products were launched in FY26: three herbicides and one insecticide.

Biologicals (PI AgSciences / PREtec platform)

Product / platformDescriptionStatus
PREtecProprietary peptide technology platform for plant immunity inductionCore IP acquired with Plant Health Care
Harpin αβRecombinant protein biostimulant promoting yield and crop qualityCommercialised; India approval received FY26
Harpina (2nd generation)Next-generation harpin productCommercialised in 25+ countries
PHC279Harpin-derived peptide boosting natural disease defenceCommercialised
PHC68949Foliar-applied biochemical nematicide — industry's first for foliar applicationUS EPA federal registration granted 3 Mar 2026; label expansion filings underway in US, Brazil, Mexico
SoljuMicrobial biofertilizerLaunched FY24–FY26
PilinBio-fungicideLaunched FY24–FY26

Biologicals run gross margins above 60% and reached roughly USD 12 mn annualised revenue as at FY26 (management commentary). Peptide products have been applied across >5 million hectares in Brazil; 500+ field trials and 1,000+ grower engagements are underway across Brazil, Mexico, Europe and the US. Management sizes the addressable nematicide market at roughly USD 750 mn and believes double-digit share is attainable.

Proprietary new chemical entity

Pioxaniliprole — India's first indigenously invented and patented insecticide, discovered in-house by PI. Targets large row crops. Domestic regulatory approval was received in fiscal 2027 (CRISIL, July 2026; AgroPages, 6 July 2026); commercial launch is guided within FY27 subject to remaining approvals and season timing. Global regulatory filings are underway; management indicated applications outside India would be filed "at the end of this year or next year" and that strategic distribution partnerships are under discussion. This is the single most important optionality in the equity story.

Pharma (PI Health Sciences)

Service lineDescription
Integrated drug discoveryTarget identification, molecule design, library synthesis, lead optimisation, biological evaluation, route synthesis. Centre of excellence in Hyderabad
Process research & developmentRoute development for APIs and intermediates
CDMO manufacturingSmall-molecule APIs, key starting materials and intermediates. Lodi (Italy) facility certified by USFDA and AIFA; AIFA GMP certification renewed Q1 FY27
Regulatory / DMF portfolio24 US Drug Master Files acquired with Archimica, across oncology, anti-ulcer and anti-arthritis classes

Six programmes were in Phase I/II/III as at Q4 FY26. Four marquee customers were onboarded in Q1 FY27, and PI signed as exclusive partner for integrated drug discovery with one biotech.

Financial Narrative

All figures ₹ Crore unless stated. Source: audited consolidated financial statements FY22–FY26; FY26 figures per statement dated 19 May 2026.

Margins, per-share and growth: notes and sources

Gross margin for FY22–FY24 is approximate, derived from management commentary rather than a single audited line item; FY25 (53%) and FY26 (58%) are as reported by the company and corroborated by CRISIL (500 bps expansion in FY26). Dividend per share for FY22–FY25 is reconstructed from payout ratios and EPS and should be treated as indicative; FY26 (₹15: ₹5 interim + ₹10 final) is as declared on 19 May 2026.

Revenue CAGR FY22–FY26: 6.1%. FY22–FY25 CAGR (pre-downturn): 14.6%. Net profit CAGR FY22–FY26: 11.9%. Screener's ten-year compounded sales growth is 12%; five-year 8%; three-year 1%; trailing twelve months –17%.

Balance sheet: notes and sources

FY22–FY24 cash/bank/investment and inventory/receivable splits are reconstructed from Screener's aggregated consolidated balance sheet and management commentary; FY25 and FY26 are taken line-by-line from the audited FY26 consolidated balance sheet and are exact. Treat FY22–FY24 sub-line detail as indicative.

The FY26 audited position is precise and worth stating directly (₹ Mn): PPE 36,783; CWIP 7,550; goodwill 6,028; other intangibles 3,386; intangibles under development 2,749; inventories 12,167; current investments 13,271; trade receivables 16,108; cash 2,833; other bank balances 18,990; contract assets 7,091; total assets 1,34,437; total equity 1,12,305; non-current borrowings 1,490; current borrowings 893; total liabilities 22,132.

Cash flow

PI has never conducted a share buyback in the period reviewed. FY26 capex per the cash flow statement was ₹11,178 Mn (₹1,118 Cr); the company separately cites FY26 capex of ₹11,508 Mn in the Q4 presentation and ₹1,100 Cr in press commentary — the range reflects gross versus net-of-advances presentation.

Ratios: notes and sources

Interest coverage for FY25 and FY26 (44.49x and 122.93x) is as computed by CRISIL. Current ratio, ROA, net debt/EBITDA and asset turnover are derived from the tables above.

Trend commentary

Revenue. Three years of 16–23% growth (FY22–FY24) gave way to deceleration (+4.1% FY25) and then contraction (–15.8% FY26). The break is attributable almost entirely to the CSM export line: CRISIL quantifies the FY26 CSM revenue decline at ~19%, driven by inventory destocking at global innovator customers, a customer shift to just-in-time procurement that deferred delivery schedules, and lower realisations. Domestic revenue fell ~7% on pricing pressure, elevated channel inventory, regulatory disruption to the biologicals portfolio for most of the year, and uneven rainfall.

The gross-margin / EBITDA-margin divergence is the defining feature of FY26. Gross margin expanded roughly 500 bps to 58% on favourable mix — higher-value new molecules, biologicals at 60%+, and a smaller share of low-margin volume. Yet EBITDA margin fell 300 bps to 25.3%. The entire gap is operating deleverage plus deliberate overhead build: pharma capability construction, biologicals market development, and regulatory and launch expenditure ahead of the NCE. Management frames 3–4% of revenue as going into future-growth platforms. This is a choice, not a failure of cost control — but it means reported margins understate the earning power of the core and overstate the payback timeline.

Return on capital is the sharpest deterioration. ROCE fell from 24% (FY24) to 15% (FY26); ROE from 21.1% to 12.4%. CRISIL identifies the cause precisely: significant investment in new capacity and growth platforms that has not yet ramped. The clearest evidence is asset turns, which management acknowledged have fallen from 2.5x to 1.5x against a stated three-year target of 2.2–2.5x. CWIP has ballooned from ₹114 Cr (FY22) to ₹1,030 Cr (FY26) — nine times — while revenue is below FY24. Two new multipurpose plants were guided to commission in Q4 FY26 and Q1/Q2 FY27.

Working capital reversed violently. The cash conversion cycle went from a best-in-class 42 days (FY25) to 119 days (FY26); net working capital days from 67 to 120. Debtor days rose from 64 to 88 and inventory days from 95 to 157. The company attributed the FY25 receivables build to higher agri-branded growth and Q4 phasing of agchem exports; FY26 added inventory accumulation as export offtake deferred. This single line explains most of the FY26 cash flow collapse: CFO fell 66% to ₹474 Cr, CFO/operating profit dropped to 48%, and free cash flow turned negative ₹632 Cr — the first negative FCF year in over a decade. Q1 FY27 showed the beginning of a correction: 19 days released, ~₹300 Cr of cash, receivable days 126 to 112.

Balance sheet remains a fortress. Tangible net worth ₹10,290 Cr, debt ₹238 Cr (CRISIL basis), gearing 0.02x, net cash ₹3,167–3,509 Cr depending on definition, rising to ₹3,794 Cr by Q1 FY27. Unencumbered cash and equivalents of ₹3,509 Cr as at 31 March 2026 with largely unutilised bank lines of ₹840 Cr. The company had no loans or other borrowings from any lender at the standalone level during FY26.

Tax rate normalised. The effective rate jumped from 11.2% (FY24) to ~22% in FY25 and FY26 as concessional-regime benefits and SEZ shelters ran their course. Management guides ~24% for FY27. This alone cost roughly 12 percentage points of net income growth between FY24 and FY25 and is a permanent structural reset, not a one-off.

Exceptional items in FY26 partially offset each other. Consolidated net exceptional gain of ₹1,031 Mn = contingent consideration write-back of ₹1,260 Mn (Therachem settlement) less ₹229 Mn of Labour Code liabilities. At standalone level, the picture is the reverse: a net exceptional loss of ₹1,323 Mn, driven by the ₹1,100 Mn impairment of the PIHS investment. Both relate to the same asset and should be read together: PI wrote down its pharma investment and simultaneously released a consideration liability associated with acquiring it.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

SegmentFY24FY25FY26

Agro Chemicals

75,30077,65064,168

Pharma

1,4702,1513,005

Less: inter-segment

402336

Total segment revenue

76,73079,77867,137

Segment Revenue (FY25–FY26)

SegmentFY25FY26

Agro Chemicals

23,91417,975

Pharma

-3,045-2,744

Inter-segment adjustment

551699

Profit before exceptional items and tax

21,42015,930

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY25FY26

Agro Chemicals PBT margin (%)

30.828.0

Pharma PBT margin (%)

-141.6-91.3

Agro Chemicals revenue YoY (%)

3.1-17.4

Pharma revenue YoY (%)

46.339.7

Agro Chemicals share of total revenue (%)

97.395.5

Pharma share of total revenue (%)

2.74.5

Segment Revenue — Segment assets — Agro Chemicals

MetricFY25FY26

Segment assets — Agro Chemicals

109,442119,736

Segment assets — Pharma

13,32514,701

Segment liabilities — Agro Chemicals

17,02718,115

Segment liabilities — Pharma

4,1704,017

Capital employed — Agro Chemicals

92,415101,621

Capital employed — Pharma

9,15510,684

Group Entities

EntityRelationshipRole

PI Industries Limited

Parent

Agchem CSM, domestic brands

PI Health Sciences Limited

Wholly-owned subsidiary

Pharma CRDMO holding

PI Health Sciences USA, LLC

Step-down

US pharma presence

PI Health Sciences Netherlands BV

Step-down

Holding vehicle

Archimica S.p.A., Italy

Step-down

API/CDMO manufacturing, Lodi

PI AgSciences Limited (formerly Plant Health Care plc)

Step-down

Global biologicals

PI AgSciences, Inc. (Nevada)

Step-down

US biologicals

Plant Health Care de Mexico S. de R.L. de C.V.

Step-down

Mexico biologicals

PI AgSciences (UK) Limited

Step-down

UK biologicals

PI AgSciences Spain, S.A.

Step-down

Spain biologicals

PI AgSciences Brasil Ltda

Step-down

Brazil biologicals

Jivagro Limited

Subsidiary

Horticulture brand

PI Life Science Research Limited

Subsidiary

Contract R&D

PI Flowtech B.V.

Subsidiary

Flow chemistry

PI Industries Management Consultancies LLC, Dubai

Subsidiary

Holding / management

PI Innoventures Limited (formerly PILL Finance and Investments Ltd)

Subsidiary

Investment activities

PI Japan Co. Limited

Subsidiary

Japan marketing arm

PI Bioferma Private Limited

Subsidiary

Fermentation

PI Fermachem Private Limited

Subsidiary

Fermentation

PII ESOP Trust

Controlled trust

Employee equity

PI Kumiai Private Limited

Joint venture

JV with Kumiai Chemical

Solinnos Agro Sciences Private Limited

Associate

JV with Mitsui Chemicals Agro (registration services)

PI Foundation

Subsidiary (approved Aug 2026)

Section 8 CSR vehicle

Income Statement

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

5,3006,4927,6667,9786,714

Other income

105166216345414

Operating profit (EBITDA ex-other income)

1,1461,5442,0302,2061,732

Depreciation and amortisation

202226308352407

Finance cost

1639445643

Profit before tax

1,0331,4441,8952,1421,696

Total tax expense

189214213482375

Net profit

8441,2301,6821,6601,321

Margin Analysis (%) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

44.046.048.053.058.0

Operating (EBITDA) margin (%)

21.623.826.527.725.8

PBT margin (%)

19.522.224.726.825.3

Net margin (%)

15.918.921.920.819.7

Effective tax rate (%)

18.314.811.222.522.1

EPS — basic (INR)

55.6281.04110.83109.4487.06

EPS — diluted (INR)

55.5880.98110.76109.4287.06

Dividend per share (INR)

6.0010.0015.0016.0015.00

Dividend payout (%)

1112141517

Revenue YoY growth (%)

15.822.518.14.1-15.8

Net profit YoY growth (%)

14.445.736.7-1.3-20.4

Balance Sheet

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

7,7918,48010,74412,24913,405

Cash and cash equivalents

371887887592283

Other bank balances

1,2001,5501,7501,9071,899

Current investments

7008501,0501,2601,327

Total debt

31646191184342

Net cash (negative = net debt)

1,9553,2413,4963,5753,167

Total equity

6,1207,1988,73110,15711,231

Goodwill

210210554554603

Other intangibles and intangibles under development

120130480503614

Property, plant and equipment

2,4522,6063,5284,2094,620

Capital work-in-progress

1141322785501,030

Inventories

1,2501,1501,3359841,217

Trade receivables

8707709201,4061,611

Cash Flow and Margin Analysis (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Cash from operating activities

5291,5012,0361,413474

Capital expenditure

3373226198381,106

Free cash flow

1921,1791,417575-632

Cash from investing activities

-110-496-1,800-1,421-612

Cash from financing activities

-177-483-222-286-171

Dividends paid

83106171228228

Share buybacks

00000

CFO / operating profit (%)

611141198148

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

Return on equity (%)

14.918.521.117.612.4

Return on assets (%)

11.415.117.514.410.3

Return on capital employed (%)

1722242315

Current ratio (x)

2.63.03.44.04.2

Debt / equity (x)

0.050.010.020.020.02

Net debt / EBITDA (x)

-1.71-2.10-1.72-1.62-1.83

Interest coverage (x)

71.639.646.144.5122.9

Asset turnover (x)

0.680.770.710.650.50

Debtor days

6043446488

Inventory days

17814412495157

Days payable

11586119117125

Cash conversion cycle (days)

1221014942119

Net working capital days

93704867120

Revenue Lines

Revenue lineFY24FY25FY26Q1 FY27

Exports (agchem CSM + pharma)

60,00063,80053,70013,542

Domestic (agri brands + biologicals)

16,66015,97813,4373,481

Total

76,66079,77867,13717,023

Region Margins & Growth (%)

Metric (%)FY25FY26Q1 FY27

Export revenue YoY

6.3-15.8-13.3

Domestic revenue YoY

-4.1-15.92.8

Export volume YoY

8.0-12.0-8.0

Domestic volume YoY

9.0-3.012.0

Pharma revenue YoY

46.339.7-25.0

Biologicals revenue YoY

15.020.050.0

Valuation Snapshot

MetricValue

Close, 11 September 2026

₹2,259 (–4.48% on the day)

52-week high / low

₹3,833 / ₹2,191

Market capitalisation

₹34,273 Cr

Shares outstanding

~151.7 mn (paid-up capital ₹15.17 Cr at ₹1 face value)

Post-Q1 FY27 reaction (12 Aug 2026)

–7.82% to ₹2,516.4

Post-Q4 FY26 reaction (20 May 2026)

–8%

Post-Q1 FY26 reaction (30 Sep 2025)

–18%

Price CAGR

Price CAGRReturn (%)

1 year

-39

3 years

-15

5 years

-8

10 years

11

Valuation Multiples

MultiplePI Industries (current)

Price / Earnings (trailing)

31.7x

Price / Book

3.05x (₹2,259 / ₹740 book value)

EV / Sales

~4.6x (EV ≈ ₹31,106 Cr on ₹6,714 Cr FY26 revenue)

EV / EBITDA

~18.0x (on FY26 EBITDA of ₹1,732 Cr)

Dividend yield

0.66%

Return on equity

11.2%

Return on capital employed

15.0%

Valuation Snapshot — Number of covering analysts

MetricValueSource

Number of covering analysts

26

stockanalysis.com

Consensus rating

Hold

stockanalysis.com

12-month consensus target price

₹2,915 (+20.96% from ₹2,410 reference)

stockanalysis.com

Morgan Stanley target

₹3,883 (cut, 20 Mar 2026)

Exchange news

Prabhudas Lilladher

HOLD, TP ₹3,618 (26 Sep 2025, CMP ₹3,488)

PL research

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

6.0010.0015.0016.0015.00

Dividend payout ratio (%)

1112141517

Dividends paid (INR Cr)

83106171228228

Credit Ratings

AgencyLong-termShort-termOutlookDateFacilities rated

CRISIL Ratings

Crisil AA+

Crisil A1+

Stable

21 Jul 2026 (reaffirmed)

₹840 Cr bank facilities

CRISIL — prior actions

Crisil AA+ / A1+

—

Stable

24 Apr 2025; 30 Jan 2024; 2 Nov 2022; 10 Aug 2021; 30 Jul 2020

Unchanged throughout

Moody's

Not rated

————

S&P Global Ratings

Not rated

————

Fitch

Not rated

————

Debt Facilities

FacilityAmount (INR Cr)Rating

Cash Credit & Working Capital Demand Loan

395

Crisil AA+/Stable

Letter of Credit & Bank Guarantee

305

Crisil A1+

Loan Equivalent Risk Limits

140

Crisil A1+

Total rated bank facilities

840

—

Analyst Conclusions

Management guidance

ItemGuidance
FY27 revenue growthPositive, low single digits — reiterated at both Q4 FY26 and Q1 FY27
PhasingH2 FY27 stronger than H1, driven by export recovery
Capital expenditure₹700–800 Cr for FY27
Effective tax rate~24%
Investment in growth platforms3–4% of revenue
New export product launches5+ in FY27
PioxaniliproleDomestic launch within FY27; global filings late 2026/2027; distribution partnerships under discussion
Pharma₹500–600 Cr revenue in 2–3 years
Electronic chemicalsUSD 100 mn in 4–5 years
BiologicalsGlobal break-even within a couple of years; Brazil sales to triple
Order bookUSD 1.0–1.2 bn confirmed

Consensus expectations

Twenty-six analysts rate PI Hold with a twelve-month target of ₹2,915 (~21% above the reference price). CRISIL expects FY27 revenue growth supported by order-book conversion, new molecule ramp-up, Pioxaniliprole, biologicals revival post regulatory resolution, and gradual pharma CRDMO ramp, with operating margin sustaining at healthy levels on stable gross margins and narrowing pharma losses. Net cash accruals are projected at ₹1,400–1,500 Cr annually.

Bull case

1. The cycle is turning and the operating leverage works in reverse. Kumiai's 70.5% H1 operating profit guidance upgrade in mid-2026 is the strongest available third-party evidence that primary demand is stabilising. CRISIL states channel inventories at global innovators are approaching normalised levels and that Q4 FY26 already showed sequential CSM growth in line with committed offtake. PI's cost base is now built for a larger business: employee expense rose 15.8% in FY26 on a 16% revenue decline. If revenue recovers toward the FY25 level of ₹7,978 Cr with gross margin anywhere near 58%, incremental gross profit drops almost entirely to EBITDA. The same negative operating leverage that took EBITDA margin from 27.7% to 22% works symmetrically.

2. PI is being valued as a contract manufacturer while becoming an IP owner. Pioxaniliprole is approved in India — the first Indian-discovered patented insecticide. Global filings are underway and management is in advanced partnering discussions. PHC68949 holds US EPA registration as the industry's only foliar-applied biochemical nematicide in a ~USD 750 mn market. Biologicals run above 60% gross margin and grew >50% in Q1 FY27. None of this existed three years ago and none of it is meaningfully in FY26 earnings.

3. The balance sheet converts the downturn into an option. Net cash ₹37,939 Mn, gearing 0.02x, interest coverage 123x, Crisil AA+ reaffirmed mid-downturn. PI can complete a full capex and R&D cycle, absorb pharma losses, maintain the dividend, and pursue acquisitions — simultaneously — without external capital. Working capital alone offers a self-funding recovery: returning from 120 days to the FY25 level of 42 days would release well over ₹1,000 Cr.

Bear case

1. Just-in-time procurement is structural, and it breaks the order book. PI entered FY26 with a USD 1.0–1.2 bn confirmed order book and delivered ₹6,714 Cr of revenue. CRISIL names prolongation of JIT procurement as a key monitorable. If innovators have permanently shifted from inventory-holding to call-off purchasing, PI's revenue visibility — the single attribute that justified a premium multiple — is structurally impaired. An order book that can be deferred indefinitely is a pipeline, not a backlog, and pipelines are worth less.

2. The capital deployed may not earn its cost. CWIP has gone from ₹114 Cr to ₹1,030 Cr in four years. Asset turns are 1.5x against a 2.2–2.5x target. ROCE has fallen from 24% to 15% and ROE to 12.4% — against an Indian cost of equity plausibly in the 12–13% range, PI is currently earning roughly nothing above its hurdle. Management raised FY27 capex guidance from ₹500–600 Cr to ₹700–800 Cr in a single quarter, mid-downturn. Meanwhile, the company wrote down ₹1,100 Mn of its own pharma investment following independent valuation while stating it "remains confident about the long-term business prospects." Pharma consumes 10.9% of capital employed for 4.5% of revenue and a ₹2,744 Mn loss, and Q1 FY27 PIHS revenue fell 25%.

3. Pricing power is eroding where PI can still see it. Q1 FY27 domestic volumes grew 12%; revenue grew 2.8%. That 9-point gap is generic price deflation arriving in the one business where PI owns the brand and the customer. CRISIL names PI's ability to counter generic pricing pressure through new launches as a monitorable. If PI cannot hold price in India with Nominee Gold and a 150,000-retailer network, the pricing outlook for off-patent CSM molecules against Chinese competition is worse. Add a below-normal monsoon forecast with developing El Niño for FY27, and the domestic recovery that is supposed to offset export weakness is itself at risk.

Catalysts and monitorables, next 12 months

Catalyst / monitorableTimingWhy it matters
Pioxaniliprole commercial launch in IndiaWithin FY27First revenue from owned IP; validates the innovator thesis
Pioxaniliprole out-licensing announcementLate 2026 / 2027Would introduce a royalty stream and reprice the stock
Q2 FY27 results (Nov 2026)Nov 2026Management said domestic pricing clarity "should emerge in Q2"
H2 FY27 export recoveryOct 2026 – Mar 2027The entire FY27 guidance rests on it. Watch sequential CSM revenue
Commissioning and ramp of the two new MPPsQ1/Q2 FY27Converts ₹1,030 Cr CWIP into revenue; the mechanical route back to 2.2x asset turns
Working capital trajectoryQuarterly19 days recovered in Q1 FY27; another 40–60 days would release ₹800 Cr+
Biologicals regulatory normalisation in IndiaFY27Restores ~20% of domestic revenue
PHC68949 US state-level registrations and Brazil/Mexico label expansionFY27Unlocks the ~USD 750 mn nematicide opportunity
PIHS revenue trajectory and loss narrowingQuarterly₹500–600 Cr target requires roughly 2x from here; another impairment would be serious
Southwest monsoon and El NiñoJun–Sep 2027 seasonCRISIL flags below-normal forecast as a direct domestic demand risk
Kumiai and other innovator guidanceQuarterlyBest available leading indicator for CSM demand
Operating margin versus CRISIL's 17–18% downgrade thresholdQuarterlyQ1 FY27 at 22%, down from 28%. Trending the wrong way
FII holding trendQuarterlyNine consecutive quarters of decline; stabilisation would signal a bottom
Any large acquisitionAny timeCRISIL flags sizeable acquisitions as credit-negative

Analyst verdict

PI Industries is a high-quality business in a bad year that has made an expensive strategic bet, and the market is currently pricing the bad year and the expense while giving little credit to the bet.

The quality is not in question. Gross margin expanded 500 basis points to 58% while revenue fell 16% — that only happens in a business with genuine contractual protection and pricing architecture. Crisil AA+ was reaffirmed mid-downturn. Net cash is ₹38 bn against gearing of 0.02x. Interest coverage is 123 times. Promoter holding is unencumbered and unchanged. The FY26 audit was unmodified with no fraud, no going-concern qualification and one governance footnote. On the operating side, PI commercialised five export molecules, launched four domestic products, added ten patents in a single quarter, won US EPA registration for a first-in-industry nematicide, and obtained Indian approval for the first insecticide ever discovered by an Indian company. This is not a company in trouble.

What it is, is a company that has chosen to spend its trough-year cash flow building four businesses it does not yet earn from. Capital work-in-progress is nine times its FY22 level. Asset turns have collapsed from 2.5x to 1.5x. ROCE has fallen from 24% to 15%. Free cash flow was negative ₹632 Cr. Pharma absorbs 11% of capital employed to lose ₹274 Cr, and management wrote down its own investment in it by ₹110 Cr while professing confidence. Capex guidance was raised mid-downturn. Every one of those decisions is defensible individually; collectively they mean the next three years of returns depend entirely on execution in businesses with no track record.

The three things that would settle the argument are all observable within twelve months: whether H2 FY27 export revenue actually recovers as guided; whether Pioxaniliprole finds a global partner; and whether working capital returns toward 60 days. If all three land, the current 31.7x trailing multiple is on trough earnings and the stock is cheap. If exports stay flat, the NCE launches only in India, and working capital stays at 120 days, then PI is a 15% ROCE business trading at three times book with a permanently reset tax rate, and the derating has further to run.

At ₹2,259, with consensus at Hold and a ₹2,915 target, the market has reached the same conclusion: credible recovery, unproven payback, wait for evidence. That is the correct posture. The bull case requires believing management's capital allocation; the bear case requires only that the recovery be slower than guided. On the evidence available in September 2026, neither is yet proven, and the asymmetry favours patience over conviction in either direction.


  • Exact group employee headcount for FY24, FY25, FY26 (third-party estimates range 3,499 to 6,762)

  • Top 10 institutional shareholders with individual stake percentages

  • Insider (non-promoter director/KMP) shareholdings

  • R&D expenditure in absolute terms and as % of revenue for FY22–FY26

  • Formal geographic revenue split by region (Americas / EMEA / APAC) — PI does not disclose this

  • Country-level revenue disclosure — not disclosed by the company

  • Number of countries of operation (website infographic numerals did not render)

  • FY22–FY24 segment revenue split between Agro Chemicals and Pharma on the current segment definition

  • Peer financials (revenue, growth, margins, R&D intensity) for UPL, Sumitomo Chemical India and Bayer CropScience India for FY26

  • Peer valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

  • Market share percentages in any served market

  • MSCI ESG rating, Sustainalytics ESG Risk Rating, CDP score

  • Board committee memberships and chairs

  • ISIN confirmation against depository records

  • CSM customer names and revenue concentration

  • Detail, subject matter and outcome of the whistle-blower complaints referenced in the FY26 CARO report

Unresolved source conflicts noted in the body: Isagro (Asia) acquisition consideration (₹345 Cr vs ₹443 Cr); incorporation year (1946 per MCA vs 1947 per company press release); FY26 capex (₹11,178 Mn cash flow vs ₹11,508 Mn presentation vs ₹1,100 Cr press commentary); CRISIL's internally inconsistent GHG intensity figures (~16% reduction FY23–FY25 vs ~6% against the FY21-base 25% target).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionClassificationBackground

Mr Narayan K. Seshadri

Non-Executive Chairperson

Non-Executive

Chartered Accountant; 42+ year career; began at Arthur Andersen, rose to Managing Partner of KPMG's India business advisory practice; only Indian partner on Andersen's Global CEO Advisory Council; founder of Tranzmute Capital. Associated with PI since 2006; Chairperson since 5 October 2016. Also on boards of SBI Life, Max Healthcare, TVS Supply Chain Solutions, Kalpataru, Re Sustainability

Mr Mayank Singhal

Vice Chairperson & Managing Director

Executive; promoter family

Engineering and Management graduate (UK). Joined PI 1996; Joint MD 2004; MD & CEO from 1 December 2009; Vice Chairperson & MD from 2019. Named "India's Best CEO" in Agriculture & Allied by Business Today (2022)

Dr Atul Kumar Gupta

Executive Director; CEO – CSM Agchem

Executive

M.Sc. Chemistry (University of Rajasthan); Ph.D. Chemistry (CSJM University, Kanpur). 25+ years at PI. DIN 10087955

Mr Rajnish Sarna

Director

Non-Independent, Non-Executive

Chartered Accountant; 30+ years' experience; ~29 years at PI. Previously Joint Managing Director — now reclassified to non-executive, a material change from prior years. DIN 06429468

Mr Arvind Singhal

Director

Non-Independent, Non-Executive; promoter family

Joint MD of PI for 22 years to December 2001; Independent Director to December 2006. MD of Wolkem India Ltd; director of Secure Meters Ltd

Dr T. S. Balganesh

Director

Non-Independent, Non-Executive

Ph.D. Medical Microbiology (Calcutta); post-doctoral at Brookhaven National Lab and Max Planck Institute; honorary doctorate, Uppsala. Former Head of Research, AstraZeneca antibacterial drug discovery, Bangalore; later MD and board member, AstraZeneca India

Ms Lisa J. Brown

Lead Independent Director

Independent

LL.B. University of Derby; registered Trade Mark Attorney; 20+ years across industrial, technology and consumer sectors; IP management, compliance, risk, corporate restructuring. Former roles at WABCO Holdings and SSL International Plc. DIN 07053317

Mr Shobinder Duggal

Independent Director

Independent

B.A.(Hons) Economics, St. Stephen's College; ICAI member; IMD Lausanne IGMP. Former CFO Nestlé India; multiple "Best CFO" awards. Also on boards of SBI Life, Kirloskar Brothers, Sanofi Consumer Healthcare India, ABB India

Ms Pia Singh

Independent Director

Independent

Wharton (Finance). Director of DLF and Chairperson of DLF's CSR Committee; began career at GE Capital. Governing Board, ICRIER

Mr Rafael Del Rio Donoso

Director

Non-Independent, Non-Executive

Agricultural Engineer, Pontificia Universidad Católica de Chile. 26 years at Syngenta Group (1997–2023); Non-Executive Chairman, Syngenta India (2022–23); President, Syngenta Latin America North

Mr Vegulaparanan Kasi Viswanathan

Independent Director

Independent

Commerce graduate, Madras University; Chartered Accountant. Former Joint MD & CFO and later MD of Bosch Limited India; Chairman of Bosch Limited 2013–2019; 17 years at Hindustan Unilever. Currently Chairperson & Independent Director, United Spirits

Mr Salil Singhal

Chairman Emeritus

Honorary (not a board vote)

Led the company from July 1979; Chairman of the Pesticides Association of India for 20 years; Co-Chairman, CII National Council on Agriculture

Governance Overview

AttributeStatus

Board size (voting directors)

11

Independent directors

4 (Brown, Duggal, Singh, Viswanathan) — CRISIL states independent directors constitute 44% of the board, implying the company's own count on a slightly different denominator

Executive directors

2 (Mayank Singhal; Dr Atul Kumar Gupta)

Chair / CEO separation

Yes — Chairperson (Seshadri) is non-executive and separate from the Managing Director. CRISIL cites this explicitly as a governance positive

Lead Independent Director

Yes — Ms Lisa J. Brown

Women on board

2 of 11 (18%)

Promoter shares encumbered

Nil. Mayank Singhal filed a declaration on 2 April 2026 under SEBI Takeover Regulations confirming no promoter shares were pledged, mortgaged or otherwise encumbered during FY26

Executive Leadership Team

NameTitle

Mr Sanjay Agarwal

Group Chief Financial Officer

Mr Jagresh Rana

Global CEO, PI AgSciences

Dr Ramesh Subramanian

Global CEO, PI Health Sciences

Dr Marco Busch

Global Head – Ag Research and Development

Mr Arunabha Raychaudhuri

Global Head – Supply Chain Management

Ms Kamali Rajesh

Global Chief People Officer

Mr Atanu Roy

Global Chief Information Officer

Mr Piyush Nagar

Global Head of Strategy and Business Development – Biologicals

Board & Management Changes

DateChange

2024–2025

Mr Rajnish Sarna transitions from Joint Managing Director to Non-Independent, Non-Executive Director

26 Oct 2025

Ms Shilpa Sachdeva ceases to be Senior Management Personnel following organisational realignment and reallocation of roles

2025

Mr Vegulaparanan Kasi Viswanathan appointed Independent Director (profile added to company leadership page in June 2025)

FY25–FY26

Appointment of Dr Ramesh Subramanian as Global CEO, PI Health Sciences; Mr Jagresh Rana as Global CEO, PI AgSciences — reflecting the shift to a platform-CEO operating model

Shareholding Trend

Holder categorySep 2023Mar 2024Mar 2025Mar 2026Jun 2026

Promoters (%)

46.0946.0946.0946.0946.09

Foreign institutional investors (%)

20.0120.2618.0615.8714.83

Domestic institutional investors (%)

23.1124.1827.4331.2031.50

Government (%)

0.150.150.150.150.15

Public (%)

10.619.298.286.697.44

Others (%)

0.020.020.010.010.01

Number of shareholders

158,268157,991167,265133,299140,999

Competitive Landscape

Key Competitors

CompetitorPrimary segment overlapPositioning relative to PI

UPL Limited (India)

Domestic + global generics, some CSM

Far larger by revenue; generics-led, leveraged balance sheet. Different model — UPL owns brands globally and carries debt; PI is contract-led and net cash

Bayer CropScience Limited (India)

Domestic branded, innovator

Innovator with own molecules; PI in-licenses; direct competitor for Indian farmer wallet share

Sumitomo Chemical India

Domestic branded + exports to parent

Structurally similar hybrid of domestic brands plus parent-directed exports; arguably PI's closest Indian analogue

Rallis India (Tata)

Domestic branded + CSM

Smaller CSM franchise; domestic overlap significant

Dhanuka Agritech

Domestic branded, ILCM

Pure domestic branded/ILCM play; direct competitor in in-licensing

Coromandel International

Domestic crop protection + fertilisers

Broader agri-input; crop protection overlap

Sharda Cropchem

Global generics, registration-led

Asset-light registration model; competes on off-patent molecules where PI faces genericisation

Best Agrolife

Domestic branded, technicals

Emerging domestic competitor

Insecticides India

Domestic branded

Domestic overlap

Godrej Agrovet (Astec LifeSciences)

CSM/technicals

Astec is a direct CSM competitor at smaller scale

Navin Fluorine International

CDMO/CSM (fluorochemistry)

Direct comparator for the pharma CDMO pivot; analysts explicitly benchmarked the Therachem deal against Navin's CDMO

Divi's Laboratories

Pharma CDMO/API

Scale benchmark for what PIHS aspires to; vastly larger

Syngenta, Corteva, BASF, FMC, Nufarm

Global innovators

Customers, not competitors, in CSM — but competitors in domestic branded and in owning molecules once PI commercialises Pioxaniliprole

Chinese generic manufacturers (fragmented)

Off-patent molecules

The principal source of price deflation; CRISIL names generic competition as a key monitorable

Syensqo, Chr. Hansen, Koppert, Certis Biologicals, Valent BioSciences

Biologicals

Competitors to PI AgSciences in biocontrol/biostimulants

Competitor Detail

MetricPI Industries (FY26)

Revenue (INR Cr)

6,714

Revenue growth YoY (%)

-15.8

EBITDA margin (%)

25.8

Net margin (%)

19.7

ROCE (%)

15.0

Net debt / equity (x)

-0.28

R&D intensity (% of revenue)

3-4 (incl. new platforms)

Recent Developments

*Litigation, regulatory actions, restructurings, layoffs. The biologicals registration suspension was a sector-wide regulatory change, not an action against PI. The Labour Codes charge was a statutory change affecting all Indian employers.

Company Snapshot

$775.3M

Revenue

6,300

Employees

$3,900M

Market Cap

2000

Founded

Rajasthan, India

Headquarters

SWOT Analysis

Strengths

  • Gross margin expanded ~500 bps to 58% in FY26 while revenue fell 16% — direct evidence that the cost-plus contract architecture with raw-material pass-through works as designed (CRISIL, July 2026; FY26 results).
  • Net cash of ₹37,939 Mn at Q1 FY27 with gearing of 0.02x and interest coverage of 122.93x (CRISIL FY26; Q1 FY27 presentation) — PI can fund a full investment cycle through a downcycle without dilution.
  • Confirmed order book of USD 1.0–1.2 bn as at 31 March 2026 (CRISIL) provides forward revenue anchoring that few Indian chemical companies can match.
  • Crisil AA+/Stable and A1+ reaffirmed on 21 July 2026 — mid-downturn, with no negative outlook change, on ₹840 Cr of facilities that remain largely unutilised.
  • 260+ patents with 10 added in Q1 FY27 alone; 700+ scientists including 200+ doctorates across four R&D sites; 90+ molecules in active pipeline with >60% in advanced phases (Q1 FY27 presentation).
  • Pioxaniliprole approved in India in FY27 — the first indigenously invented and patented insecticide from an Indian company, converting PI from service provider to IP owner.
  • Biologicals grew >50% YoY in Q1 FY27 at >60% gross margin, with PHC68949 receiving US EPA federal registration on 3 March 2026 as the industry's first foliar-applied biochemical nematicide.
  • Zero promoter share encumbrance confirmed for FY26 (declaration filed 2 April 2026); promoter holding stable at 46.09% since FY24.

Weaknesses

  • Free cash flow turned negative ₹632 Cr in FY26 — the first negative FCF year in the decade reviewed — as CFO collapsed 66% to ₹474 Cr against capex of ₹1,106 Cr.
  • Cash conversion cycle deteriorated from 42 days (FY25) to 119 days (FY26); debtor days from 64 to 88; inventory days from 95 to 157.
  • ROCE fell from 24% (FY24) to 15% (FY26); ROE from 21.1% to 12.4% — CRISIL identifies this as a key monitorable and attributes it to capacity not yet ramped.
  • Asset turns at 1.5x against management's own 2.2–2.5x three-year target, with CWIP at ₹1,030 Cr versus ₹114 Cr in FY22 — a nine-fold increase in unproductive capital.
  • Pharma consumed 10.9% of group capital employed to generate 4.5% of revenue and a ₹2,744 Mn pre-tax loss in FY26, and PI wrote down ₹1,100 Mn against its own PIHS investment at 31 March 2026 following an independent valuation.
  • Customer concentration cannot be assessed from public disclosure, and the pyroxasulfone dependency is material enough to anchor analyst questioning on earnings calls.
  • Effective tax rate reset permanently from 11.2% (FY24) to ~22% (FY25–FY26), guided to ~24% for FY27 — a structural earnings headwind independent of operations.

Opportunities

  • Pioxaniliprole global out-licensing. Management confirmed "advanced talks in certain cases, in certain geographies" with global distribution partners; filings outside India planned for late 2026/2027. A successful out-licence would introduce a high-margin royalty stream PI has never had.
  • Foliar nematicide market of ~USD 750 mn with management believing double-digit share is attainable, and Brazil sales guided to triple.
  • Restocking-led recovery. CRISIL expects channel inventories at global innovators to approach normalised levels through FY27, with Q4 FY26 already showing sequential CSM growth in line with committed customer offtake.
  • Electronic chemicals USD 100 mn target in 4–5 years, with 25% of new CSM enquiries now non-agrochemical — evidence the diversification is being pulled by customers, not pushed by PI.
  • Pharma scale-up to ₹500–600 Cr in 2–3 years, supported by four marquee customers onboarded in Q1 FY27 and a first exclusive integrated drug-discovery mandate.
  • Working capital release. Q1 FY27 already freed ~₹300 Cr with 19 days of improvement; returning to the FY25 42-day cycle would release several hundred crore more.
  • Two new multipurpose plants commissioning in Q4 FY26 and Q1/Q2 FY27 convert ₹1,030 Cr of CWIP into revenue-generating capacity and are the mechanical route back to 2.2x+ asset turns.
  • M&A optionality. ₹38 bn of net cash and management's stated continued evaluation of inorganic opportunities, in a sector where distressed assets are plentiful mid-cycle.

Threats

  • Just-in-time procurement by innovator customers is a permanent structural change, not a cyclical one. CRISIL explicitly names "any prolongation of destocking or of the just-in-time procurement approach" as a key monitorable.
  • Below-normal southwest monsoon forecast for FY27 amid developing El Niño conditions (CRISIL) directly threatens the ~20% of revenue that is domestic, which is already suffering pricing pressure.
  • Genericisation of the existing CSM portfolio. CRISIL names this as an inherent risk; pyroxasulfone's maturity is the live case.
  • Chinese generic price deflation. Q1 FY27 domestic volumes grew 12% but revenue only 2.8% — a 9-point price/mix gap.
  • Regulatory risk in biologicals. India's temporary discontinuation of biological product registration disrupted ~20% of domestic revenue for most of FY26 and could recur.
  • Pharma execution risk. Biotech funding slowdown and "geopolitical challenges" were explicitly cited by management as constraining CRDMO momentum; Q1 FY27 PIHS revenue fell 25%.
  • Sustained foreign investor exit. FII holding fell from 20.26% (March 2024) to 14.83% (June 2026) across nine consecutive quarters; a stock down 39% in twelve months with continued FII selling faces persistent supply.
  • CRISIL's downgrade triggers are within reach if the cycle extends: operating profitability below 17–18% (currently 22% in Q1 FY27, down from 28%) combined with weak ROCE, or a further working-capital stretch. The margin trajectory is moving toward, not away from, that threshold.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Apr 2025CRISIL reaffirms Crisil AA+/Stable and Crisil A1+Rating stability through the downturn
19–20 May 2025FY25 results: standalone revenue ₹75,712 Mn (+5.96%); consolidated revenue ₹79,778 Mn (+4.1%); consolidated PAT ₹16,602 Mn; final dividend declaredLast year of growth before the FY26 contraction
Jun 2025Mr Vegulaparanan Kasi Viswanathan added to the board as Independent DirectorGovernance strengthening; deep MNC operating experience
Q1 FY26 (Jun 2025 quarter)Revenue ₹1,900 Cr; PAT ₹400 Cr. Consolidated revenue declined ~8% YoY; agchem exports –14% with volumes –9%; domestic +6%; excluding biologicals, domestic +13%First quarter of the downturn. Gross margin expanded 570 bps to 57.4% but OPM fell 90 bps to 27.3% — the margin divergence pattern begins
Q1 FY26Indian regulator temporarily discontinues registration of agricultural biological productsHits a segment representing ~20% of domestic sales; impacts Q1 and Q2 FY26 and persists for most of the fiscal year
Q1 FY26Order book disclosed at ~USD 1.2 bn; 6–7 new products planned for FY26 commercialisationRevenue-visibility anchor
Q1 FY26Pioxaniliprole filed for registration in IndiaFirst in-house NCE reaches the regulatory stage
Aug 2025Q1 FY26 earnings call; management maintains mid-single-digit FY26 revenue growth guidance with 25–27% OPMGuidance subsequently missed
14 Aug 2025Annual General Meeting heldRoutine
30 Sep 2025Stock falls 18% on weak Q1 outlook and biologics regulatory headwindBeginning of the derating
26 Oct 2025Ms Shilpa Sachdeva ceases to be Senior Management PersonnelOrganisational realignment
20 Nov 2025Q2 FY26 results published (Sep 2025 quarter: revenue ₹1,872 Cr, PAT ₹409 Cr)Sequential resilience masking YoY decline
21 Nov 2025India's four consolidated Labour Codes take effectTriggers a ₹209 Mn consolidated incremental employee-benefit liability, recognised as an exceptional item across Q3/Q4 FY26
Dec 2025 (Q3 FY26)Contingent consideration write-back of ₹1,260 Mn on the Therachem acquisition following renegotiated one-time settlementExceptional gain; also signals PIHS now has an in-house global BD team, removing the need for external business-development support
5 Feb 2026Board meeting scheduled to consider Q3 FY26 results and an interim dividend–
12–13 Feb 2026Q3 FY26 results: revenue ₹13,757 Mn, down 28% YoY (exports –31% on delivery-schedule adjustments; domestic –7.9%); PAT ₹311 Cr; interim dividend ₹5/share declaredThe worst quarter of the cycle. Net working capital deteriorates to 139 days from 115
Q3 FY26Harpin αβ receives approval in India; S&P Global Corporate Sustainability ranking improves to 98th percentile; capex guidance for FY27 given as ₹500–600 Cr–
3 Mar 2026US EPA grants federal registration for PHC68949, the agriculture industry's first foliar-applied biochemical nematicide. PI AgSciences' third US active ingredientMaterially de-risks the biologicals growth case; opens a ~USD 750 mn market
13 Mar 2026Kumiai Chemical cuts its agriculture chemicals segment FY26 forecast by 6%Read-through negative for PI's largest CSM relationship
18 Mar 2026PI schedules analyst and investor meetings for 23–25 March 2026–
20 Mar 2026Morgan Stanley cuts PI Industries target price to ₹3,883 citing agchem export weaknessSell-side capitulation begins
2 Apr 2026Mayank Singhal files promoter declaration confirming nil encumbrance on promoter shares during FY26Governance positive
19 May 2026FY26 results. Consolidated revenue ₹67,137 Mn (–16%); EBITDA ₹17,053 Mn (–22%, 25% margin); PAT ₹13,208 Mn (–20%). Q4: revenue ₹15,652 Mn (–12%), PAT ₹2,002 Mn (–39%). Gross margin 58% (+507 bps). Capex ₹11,508 Mn. Final dividend ₹10/share; total ₹15/shareThe trough year confirmed
31 Mar 2026 (disclosed 19 May)₹1,100 Mn impairment provision against the standalone carrying value of the PIHS investment, based on independent valuation, following business lossesManagement "remains confident about the long-term business prospects of PIHS" — but has written down its own investment
20 May 2026Shares fall 8% post Q4 results–
20 May 2026Q4 FY26 earnings call. FY27 guidance: positive growth at low single digits; capex ₹700–800 Cr; pharma target ₹500–600 Cr in 2–3 years; electronic chemicals USD 100 mn in 4–5 years; biologicals break-even in "a couple of years." SAP S/4HANA implementation confirmed complete. Asset turns acknowledged down from 2.5x to 1.5xCapex guidance raised from the ₹500–600 Cr given one quarter earlier — an unusual move in a downcycle
Jul 2026Pioxaniliprole receives Indian regulatory approval — India's first indigenously invented and patented insecticide. Launch guided within FY27The single most important positive catalyst
21 Jul 2026CRISIL reaffirms Crisil AA+/Stable / Crisil A1+ on ₹840 Cr of bank facilities. Notes interest coverage of 123x, gearing 0.02x, net worth ₹10,290 CrCredit quality unimpaired despite the earnings decline
Aug 2026Kumiai Chemical delivers a 70.5% first-half operating profit guidance upgradeStrongest available signal that primary demand is stabilising
11–12 Aug 2026Q1 FY27 results: revenue ₹17,023 Mn (–10%); EBITDA ₹3,693 Mn (–29%, 22% margin); PAT ₹2,442 Mn (–39%). Exports ₹13,542 Mn (–13.3%, volumes –8%); domestic ₹3,481 Mn (+2.8%, volumes +12%); PIHS ₹542 Mn (–25%). Biologicals +50%. Net cash ₹37,939 Mn. NWC down 19 days, releasing ~₹300 Cr. OCF ₹6,395 Mn. Capex ₹2,685 MnRevenue decline moderating; working capital repairing; margin still compressing
12 Aug 2026Shares fall 7.82% to ₹2,516.4, near the bottom of the 52-week range–
12 Aug 2026Board approves incorporation of PI Foundation, a Section 8 wholly-owned subsidiary for CSR, initial capital ₹100,000–
Q1 FY27Three new molecules commercialised, including a new peptide-based biological product launched in the US; four marquee pharma customers onboarded; exclusive integrated drug-discovery partnership signed; AIFA GMP renewed at Lodi; 10 new patents addedOperational execution continues despite the P&L
26 Aug – 3 Sep 2026Series of analyst/investor meeting intimations under Regulation 30; one-on-ones with Fortitude Fund, Aberdeen and Kotak Mutual Fund on 3, 9 and 10 SeptemberActive IR engagement during the derating
11 Sep 2026Share closes at ₹2,259, down 4.48% on the day; market cap ₹34,273 Cr; stock down 39% over twelve months–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (%): Agro Chemicals share of total revenue fell from 97.3% in FY2025 to 95.5% in FY2026.
Pi Industries Ltd — Revenue by Segment (%)
Series (%)FY2025FY2026
Agro Chemicals share of total revenue97.395.5
Pharma share of total revenue2.74.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.